These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15571807)

  • 1. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach.
    Groll M; Huber R
    Biochim Biophys Acta; 2004 Nov; 1695(1-3):33-44. PubMed ID: 15571807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.
    Groll M; Koguchi Y; Huber R; Kohno J
    J Mol Biol; 2001 Aug; 311(3):543-8. PubMed ID: 11493007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
    Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
    J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome.
    Groll M; Nazif T; Huber R; Bogyo M
    Chem Biol; 2002 May; 9(5):655-62. PubMed ID: 12031672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.
    Grover A; Shandilya A; Bisaria VS; Sundar D
    BMC Genomics; 2010 Dec; 11 Suppl 4(Suppl 4):S15. PubMed ID: 21143798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome.
    Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L
    Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macyranones: Structure, Biosynthesis, and Binding Mode of an Unprecedented Epoxyketone that Targets the 20S Proteasome.
    Keller L; Plaza A; Dubiella C; Groll M; Kaiser M; Müller R
    J Am Chem Soc; 2015 Jul; 137(25):8121-30. PubMed ID: 26050527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of proteasome inhibitors.
    Bo Kim K; Fonseca FN; Crews CM
    Methods Enzymol; 2005; 399():585-609. PubMed ID: 16338383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nature of pharmacophore influences active site specificity of proteasome inhibitors.
    Screen M; Britton M; Downey SL; Verdoes M; Voges MJ; Blom AE; Geurink PP; Risseeuw MD; Florea BI; van der Linden WA; Pletnev AA; Overkleeft HS; Kisselev AF
    J Biol Chem; 2010 Dec; 285(51):40125-34. PubMed ID: 20937826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent and non-covalent reversible proteasome inhibition.
    Beck P; Dubiella C; Groll M
    Biol Chem; 2012 Oct; 393(10):1101-20. PubMed ID: 23091276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
    Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
    J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
    Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
    J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
    Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
    Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors.
    Ettari R; Bonaccorso C; Micale N; Heindl C; Schirmeister T; Calabrò ML; Grasso S; Zappalà M
    ChemMedChem; 2011 Jul; 6(7):1228-37. PubMed ID: 21506279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chaperone-assisted assembly of the proteasome core particle.
    Matias AC; Ramos PC; Dohmen RJ
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):29-33. PubMed ID: 20074030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly.
    Arendt CS; Hochstrasser M
    EMBO J; 1999 Jul; 18(13):3575-85. PubMed ID: 10393174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic characterization of the chymotryptic activity of the 20S proteasome.
    Stein RL; Melandri F; Dick L
    Biochemistry; 1996 Apr; 35(13):3899-908. PubMed ID: 8672420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathiolation of the proteasome is enhanced by proteolytic inhibitors.
    Demasi M; Shringarpure R; Davies KJ
    Arch Biochem Biophys; 2001 May; 389(2):254-63. PubMed ID: 11339815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors.
    Sprangers R; Li X; Mao X; Rubinstein JL; Schimmer AD; Kay LE
    Biochemistry; 2008 Jul; 47(26):6727-34. PubMed ID: 18540636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.